Epirubicin

Advanced Solid Tumor

InSilico Medicine Hong Kong LimitedPhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 60/ 100
Competitive Position: 59/ 100

Competitive context

547 Active assets in the Advanced Solid Tumor cohort.

Asset / Sponsor	Phase	Rating
Toripalimab Nanjing Immunophage Biotech Co., Ltd	Phase 2	B
Cyclophosphamide National Cancer Institute (NCI)	Phase 3	B
Pyrotinib LaNova Medicines Limited	Phase 3	B
LENVATINIB LaNova Medicines Limited	Phase 2	B
Pembrolizumab InSilico Medicine Hong Kong Limited	Phase 4	B

View all 50 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant

BBB

Indicative ·

74 / 100

Lung Non-Small Cell Squamous CarcinomaDormant

BBB

Indicative ·

72 / 100

Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant

BBB

Indicative ·

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.